Quick Answer
BioAtla, Inc. reported Diluted EPS of $1.01 per share (loss) for fiscal year 2025.
BioAtla, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.01 | +29.9% |
| 2024 | -$1.44 | +44.2% |
| 2023 | -$2.58 | +5.8% |
| 2022 | -$2.74 | +0.7% |
| 2021 | -$2.76 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.27 | -22.7% | +15.6% |
| June 30, 2025 | -$0.32 | +27.3% | -23.1% |
| March 31, 2025 | -$0.26 | +45.8% | -18.2% |
| September 30, 2024 | -$0.22 | +68.6% | +50.0% |
| June 30, 2024 | -$0.44 | +41.3% | +8.3% |
| March 31, 2024 | -$0.48 | +17.2% | +31.4% |
| September 30, 2023 | -$0.70 | -1.4% | +6.7% |
| June 30, 2023 | -$0.75 | +2.6% | -29.3% |
- BioAtla, Inc. showed an increase of +29.9% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, BioAtla, Inc.’s diluted eps has grown by 63.4% (from $2.76 per share (loss) to $1.01 per share (loss)).
- The most recent figure is from BioAtla, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: